Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.50 |
| ▸ | CTSK | P43235 | 2/20 | 0.50 |
| ▸ | PPARA | Q07869 | 5/20 | 0.46 |
| ▸ | PPARG | P37231 | 4/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.45 |
| ▸ | CDC25B | P30305 | 4/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.45 |
| ▸ | CDC25A | P30304 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30775625 | 1.00 | CTSS (0.50) | CTSSCTSKPPARAPPARGPTPN1 | |
| SCHEMBL24812939 | 0.89 | CTSS (0.47) | CTSSCTSKPPARAPPARGCA2 | |
| SCHEMBL19602658 | 0.89 | CTSS (0.47) | CTSSCTSKPPARAPPARGCA2 | |
| SCHEMBL2212074 | 0.89 | PPARA (0.55) | CTSSCTSKPPARAPPARGPTPN1 | |
| SCHEMBL12018371 | 0.89 | PPARA (0.55) | CTSSCTSKPPARAPPARGPTPN1 | |
| SCHEMBL1414711 | 0.89 | PPARA (0.55) | CTSSCTSKPPARAPPARGPTPN1 | |
| SCHEMBL3449019 | 0.89 | PPARA (0.55) | CTSSCTSKPPARAPPARGPTPN1 | |
| SCHEMBL400187 | 0.89 | PPARA (0.55) | CTSSCTSKPPARAPPARGPTPN1 | |
| SCHEMBL400186 | 0.89 | PPARA (0.55) | CTSSCTSKPPARAPPARGPTPN1 | |
| SCHEMBL12055688 | 0.89 | PPARA (0.55) | CTSSCTSKPPARAPPARGPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4358954-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-117561058-A | CDK2 inhibitors and methods of use thereof | 塞迪拉治疗股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| WO-2022272106-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022272106-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK2AP2 | CTSS 2361/4885CTSK 1055/4885PPARA 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.